Universidade Federal do Rio Grande - Rio Grande (RS), Brazil.
Rev Assoc Med Bras (1992). 2023 May 19;69(5):e20221163. doi: 10.1590/1806-9282.20221163. eCollection 2023.
The objective of this study, carried out at the university hospital of the Federal University of Rio Grande, was to assess whether the treatment of chronic hepatitis C with direct-acting antivirals and the sustained virological response will affect the metabolic influences of the hepatitis C virus and whether these effects will vary according to genotypes and virus load.
This is an intervention pre-post study, carried out from March 2018 to December 2019, evaluating 273 hepatitis C virus patients treated with direct-acting antivirals. Inclusion criteria included being monoinfected with hepatitis C virus and achieving sustained virological response . Exclusion criteria included the presence of decompensated cirrhosis or co-infected with hepatitis B virus or human immunodeficiency virus. Genotypes, genotype 1 subtypes, and hepatitis C virus viral load were analyzed. Glucose metabolism was evaluated by the Homeostasis Model Assessment-insulin resistance indices: Homeostasis Model Assessment-β, TyG, and HbA1c, measured at the beginning of treatment and in sustained virological response. Statistical analysis with a T test by paired comparison of the means of the variables in the pretreatment and in the sustained virological response.
Homeostasis Model Assessment-insulin resistance analysis: there were no significant differences between pretreatment and sustained virological response. Homeostasis Model Assessment-β analysis: significant increase in genotype 1 patients (p<0.028). TyG index analysis: significant increase in genotype 1b (p<0.017), genotype 3 (p<0.024), and genotype non-1 with low viral load (p<0.039). HbA1c analysis: significant decrease in genotype 3 (p<0.001) and genotype non-1 patients with low viral load (p<0.005).
We detected significant metabolic influences after sustained virological response: impairment in lipid profile and improvements in the glucose metabolism. We found significant differences in genotype dependence, genotype 1 subtypes, and viral load.
本研究在联邦大学的大学附属医院进行,旨在评估慢性丙型肝炎的直接作用抗病毒治疗和持续病毒学应答是否会影响丙型肝炎病毒的代谢影响,以及这些影响是否会因基因型和病毒载量而有所不同。
这是一项干预前后研究,于 2018 年 3 月至 2019 年 12 月进行,评估了 273 例接受直接作用抗病毒治疗的丙型肝炎病毒患者。纳入标准包括单纯丙型肝炎病毒感染和实现持续病毒学应答。排除标准包括失代偿性肝硬化或乙型肝炎病毒或人类免疫缺陷病毒合并感染。分析基因型、基因型 1 亚型和丙型肝炎病毒病毒载量。通过稳态模型评估胰岛素抵抗指数:稳态模型评估-β、TyG 和 HbA1c 来评估葡萄糖代谢,在治疗开始时和持续病毒学应答时进行测量。采用 T 检验对治疗前和持续病毒学应答时的变量均值进行配对比较进行统计分析。
稳态模型评估胰岛素抵抗分析:治疗前和持续病毒学应答之间没有显著差异。稳态模型评估-β 分析:基因型 1 患者显著增加(p<0.028)。TyG 指数分析:基因型 1b(p<0.017)、基因型 3(p<0.024)和低病毒载量的非基因型 1 患者显著增加(p<0.039)。HbA1c 分析:基因型 3(p<0.001)和低病毒载量的非基因型 1 患者显著下降(p<0.005)。
我们在持续病毒学应答后检测到明显的代谢影响:脂质谱受损,葡萄糖代谢改善。我们发现基因型依赖性、基因型 1 亚型和病毒载量存在显著差异。